2006, Biosimilars and Labelling

Four Crucial Questions about the Humira Biosimilar Price War (rerun)

Drug Channels

OCTOBER 3, 2023

Since I published the article below in July 2023 , there have been three notable market develpoments: IQVIA has reported that as as of mid-2023, there was almost no adoption of Amgen's Amjevita, the first Humira biosimilar. Boehringer-Ingelheim launched an unbranded, low WAC version of its interchangeable biosimilar.

Biosimilars

Biosimilars Drug Pricing Labelling

Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

Drug Channels

SEPTEMBER 24, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. There’s still time to request an invite to the inaugural Drug Channels Leadership Forum. Attendance will be highly limited. We have already begun extending invitations, so apply now to be considered. Click here to view the full agenda.

Biosimilars

Biosimilars Labelling

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? (rerun)

Drug Channels

DECEMBER 9, 2024

During Friday's webinar, Ill share some updated thoughts on biosimilars and PBMs private label products. The Humira biosimilar market just took another step forwardbut remains far from its ideal state. As you will see below, CVS Healths formulary actions led to rapid uptake of a low-list-price biosimilar.

Biosimilars

Biosimilars Labelling

Drug Channels News Roundup, September 2024: Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

Drug Channels

SEPTEMBER 24, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. There’s still time to request an invite to the inaugural Drug Channels Leadership Forum. Attendance will be highly limited. We have already begun extending invitations, so apply now to be considered. Click here to view the full agenda.

Biosimilars

Biosimilars Labelling

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars (rerun)

Drug Channels

DECEMBER 11, 2023

One update: CVS Caremark's 2024 formulary for patient-administered autoimmune products prefers: Humira Hyrimoz (the high WAC Sandoz biosimilar) adalimumab-adaz (the unbranded, low WAC Sandoz biosimilar) Perhaps coincidentally, Sandoz products are marketed by Cordavis, the new business described in today's rerun.

Biosimilars

Biosimilars Labelling

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble?

Drug Channels

SEPTEMBER 4, 2024

The Humira biosimilar market just took another step forward—but remains far from its ideal state. Last week, Cigna’s Express Scripts announced that it that will follow CVS Health’s CVS Caremark business and remove Humira from its largest commercial formulary in favor of multiple biosimilars. All rights reserved.

Biosimilars

Biosimilars Labelling

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars

Drug Channels

SEPTEMBER 6, 2023

CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. Rather than announce multiple biosimilars for its pharmacy benefit manager (PBM) formulary, the company will instead launch Cordavis, a new subsidiary that will market a private label, low-list-price version of Sandoz’ Hyrimoz.

Biosimilars

Biosimilars Labelling

When Payers Become Producers: Inside the PBM Private-Labeling Trend

Drug Channels

AUGUST 16, 2024

Benjamin reviews the growing trend of PBMs vertically integrating into the production of biosimilars. The findings shed light on payers' view of biosimilar conpetition, contracting challenges, and other issues. Click here to learn more about MMIT’s Custom Market Research offering for biosimilar manufacturers.

Labelling

Labelling Biosimilars

EU pharmaceutical legislation revisions: what are the implications for biopharma?

European Pharmaceutical Review

DECEMBER 20, 2023

Changes to regulatory data protection periods are of particular interest to biopharma” Changes to regulatory data protection (RDP) periods are of particular interest to biopharma (originators and generic / biosimilar manufacturers). analysis (Source: L.E.K) By contrast, orphan drugs could become less profitable, more risky investments.

Biosimilars

Biosimilars Labelling Documentation

A history of Johnson & Johnson

pharmaphorum

FEBRUARY 26, 2021

Robert Wood’s granddaughter, Mary Lea, was the first baby to be used on the baby powder label. In 2006, J&J acquired Pfizer Consumer Healthcare for $16.6 Johnson’s Baby Powder also went on sale during this year and was extremely successful. billion in cash.

Vaccines

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

PharmaShots

APRIL 13, 2023

by the sales of Humira 2006 Johnson & Johnson recorded global sales of $53.3B in the year 2006, thereby depicting a growth rate of 5.6%. in revenue following the addition of Pfizer’s consumer health business in the year 2006. in revenue following the addition of Pfizer’s consumer health business in the year 2006.

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

pharmaphorum

NOVEMBER 19, 2020

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen are closing in after the FDA accepted a filing for their cut-price rival.

Biosimilars

Biosimilars Labelling

Drug Channels Outlook 2025 (NEW Live Video Webinar)

Drug Channels

NOVEMBER 12, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Fein will clearly distinguish his opinions and interpretations from the objective facts and data. He will draw from exclusive information found in DCI's economic reports. Read on for full details on pricing and registration.

Drug Pricing

Drug Pricing Biosimilars Labelling

Pharmacist Digest

Four Crucial Questions about the Humira Biosimilar Price War (rerun)

Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

Trending Sources

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? (rerun)

Drug Channels News Roundup, September 2024: Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars (rerun)

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble?

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars

When Payers Become Producers: Inside the PBM Private-Labeling Trend

EU pharmaceutical legislation revisions: what are the implications for biopharma?

A history of Johnson & Johnson

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

Drug Channels Outlook 2025 (NEW Live Video Webinar)

Stay Connected